C5a/C5aR pathway is essential for the pathogenesis of murine viral fulminant hepatitis by way of potentiating Fgl2/fibroleukin expression

Hepatology

Volumn 60, Issue 1, 2014, Pages 114-124

  Xu, Gui lian ^a   Chen, Jian ^a   Yang, Fei ^a   Li, Gui qing ^a   Zheng, Li xin ^b   Wu, Yu zhang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5A RECEPTOR; FIBRINOGEN LIKE PROTEIN 2; FIBROLEUKIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN; SYNAPTOPHYSIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; DISEASE PREDISPOSITION; ENZYME INHIBITION; FEMALE; HEPATITIS; HUMAN; HUMAN TISSUE; IN VITRO STUDY; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; UPREGULATION; VIRUS ATTENUATION; VIRUS PATHOGENESIS;

ACUTE DISEASE; ANIMALS; COMPLEMENT C5A; FEMALE; FIBRINOGEN; HEPATITIS, VIRAL, ANIMAL; HUMANS; LIVER FAILURE, ACUTE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; MURINE HEPATITIS VIRUS; RECEPTOR, ANAPHYLATOXIN C5A; SEVERITY OF ILLNESS INDEX; UP-REGULATION;

EID: 84903266513     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.27114     Document Type: Article

References (34)

1. Lee WM. Acute liver failure. N Engl J Med 1993;329:1862-1872.
2. Spaan W, Cavanagh D, Honinek M. Coronaviruses. In: Van Regenmortel MHV, Neurath AR (eds.). Immuno-chemistry of Viruses. II. The Basis for Serodiagnosis and Vaccines. Amsterdam: Elsevier Science Publishers; 1990. p 359.
3. MacPhee PJ, Dindzans VJ, Fung LS, Levy GA. Acute and chronic changes in the microcirculation of the liver in inbred strains of mice following infection with mouse hepatitis virus type 3. Hepatology 1985;5:649-660.
4. Wetsel RA, Fleischer DT, Haviland DL. Deficiency of the murine fifth complement component (C5). A 2-base pair gene deletion in a 5'-exon. J Biol Chem 1990; 265:2435-2440.
5. Karp CL, Grupe A, Schadt E, Ewart SL, Keane-Moore M, Cuomo PJ, et al. Identification of complement factor 5 as a susceptibility locus for experimental allergic asthma. Nat Immunol 2000;1:221-226.
6. Patel SN, Berghout J, Lovegrove FE, Ayi K, Conroy A, Serghides L, et al. C5 deficiency and C5a or C5aR blockade protects against cerebral malaria. J Exp Med 2008;205:1133-1143.
7. Hillebrandt S, Wasmuth HE, Weiskirchen R, Hellerbrand C, Keppeler H, Werth A, et al. Complement factor 5 is a quantitative trait genethat modifies liver fibrogenesis in mice and humans. Nat Genet 2005;37:835-843.
8. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005;23:821-852.
9. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, McGuire SR, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 2006;12:682-687.
10. Perret JJ, Raspe E, Vassart G, Parmentier M. Cloning and functional expression of the canine anaphylatoxin C5a receptor. Evidence for high interspecies variability. Biochem J 1992;288:911-917.
11. Cain SA, Monk PN. The orphan receptor C5L2 has high affinity binding sites for complement fragments C5a and C5a des-Arg (74). J Biol Chem 2002;277:7165-7169.
12. Chen NJ, Mirtsos C, Suh D, Lu YC, Lin WJ, McKerlie C, et al. C5L2 is critical for the biological activities of the anaphylatoxins C5a and C3a. Nature 2007;446:203-207.
13. Ward PA. The harmful role of C5a on innate immunity in sepsis. J Innate Immun 2010;2:439-445.
14. Rittirsch D, Flierl MA, Ward PA. Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008;8:776-787.
15. Rittirsch D, Flierl MA, Nadeau BA, Day DE, Huber-Lang M, Mackay CR, et al. Functional roles for C5a receptors in sepsis. Nat Med 2008;14:551-557.
16. Abecassis M, Falk JA, Makowka L, Dindzans VJ, Falk RE, Levy GA. 16, 16 Dimethyl prostaglandin E2 prevents the development of fulminant hepatitis and blocks the induction of monocyte/macrophage procoagulant activity after murine hepatitis virus strain 3 infection. J Clin Invest 1987;80:881-889.
17. Yang C, Chen Y, Guo G, Li H, Cao D, Xu H, et al. Expression of B and T lymphocyte attenuator (BTLA) in macrophages contributes to the fulminant hepatitis caused by murine hepatitis virus strain-3. Gut 2013;62:1204-1213.
18. Li C, Fung LS, Chung S, Crow A, Myers-Mason N, Phillips MJ, et al. Monoclonal antiprothrombinase (3D4.3) prevents mortality from murine hepatitis virus (MHV-3) infection. J Exp Med 1992;176:689-697.
19. Ding JW, Ning Q, Liu MF, Lai A, Leibowitz J, Peltekian KM, et al. Fulminant hepatic failure in murine hepatitis virus strain 3 infection: tissue-specific expression of a novel Fgl2 prothrombinase. J Virol 1997;71:9223-9230.
20. Ning Q, Lakatoo S, Liu M, Yang W, Wang Z, Phillips MJ, et al. Induction of prothrombinase Fgl2 by the nucleocapsid protein of virulent mouse hepatitis virus is dependent on host hepatic nuclear factor-4 alpha. J Biol Chem 2003;278:15541-15549.
21. Marsden PA, Ning Q, Fung LS, Luo X, Chen Y, Mendicino M, et al. The Fgl2/fibroleukin prothrombinase contributes to immunologically mediated thrombosis in experimental and human viral hepatitis. J Clin Invest 2003;112:58-66.
22. Finch AM, Wong AK, Paczkowski NJ, Wadi SK, Craik DJ, Fairlie DP, et al. Low-molecular-weight peptidic and cyclic antagonists of the receptor for the complement factor C5a. J Med Chem 1999;42:1965-1974.
23. McGilvray ID, Lu Z, Wei AC, Dackiw AP, Marshall JC, Kapus A, et al. Murine hepatitis virus strain 3 induces the macrophage prothrombinase fgl-2 through p38 mitogen-activated protein kinase activation. J. Biol Chem 1998;273:32222-32229.
24. Schieferdecker HL, Rothermel E, Timmermann A, Gotze O, Jungermann K. Anaphylatoxin C5a receptor mRNA is strongly expressed in Kupffer and stellate cells and weakly in sinusoidal endothelial cells but not in hepatocytes of normal rat liver. FEBS Lett 1997;406:305-309.
25. Thangam EB, Venkatesha RT, Zaidi AK, Jordan-Sciutto KL, Goncharov DA, Krymskaya VP, et al. Airway smooth muscle cells enhance C3a-induced mast cell degranulation following cell-cell contact. FASEB J 2005;19:798-800.
26. Hawlisch H, Belkaid Y, Baelder R, Hildeman D, Gerard C, Köhl J. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity 2005;22:415-426.
27. Pang L, Sawada T, Decker SJ, Saltiel AR. Inhibition of MAP kinase kinase blocks the differentiation of PC-12 cells induced by nerve growth factor. J Biol Chem 1995;270:13585-13588.
28. Dudley DT, Pang L, Decker SJ, Bridges AJ, Saltiel AR. A synthetic inhibitor of the mitogen-activated protein kinase cascade. Proc Natl Acad Sci U S A 1995;92:7686-7689.
29. Cuenda A, Rouse J, Doza YN, Meier R, Cohen P, Gallagher TF, et al. SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1. FEBS Lett 1995;364:229-233.
30. Kumar S, McDonnell PC, Gum RJ, Hand AT, Lee JC, Young PR. Novel homologues of CSBP/p38 MAP kinase: activation, substrate specificity and sensitivity to inhibition by pyridinyl imidazoles. Biochem Biophys Res Commun 1997;235:533-538.
31. Schaeffer V, Cuschieri J, Garcia I, Knoll M, Billgren J, Jelacic S, et al. The priming effect of C5a on monocytes is predominantly mediated by the p38 MAPK pathway. Shock 2007;27:623-630.
32. Chiou WF, Tsai HR, Yang LM, Tsai WJ. C5a differentially stimulates the ERK1/2 and p38 MAPK phosphorylation through independent signaling pathways to induced chemotactic migration in RAW264.7 macrophages. Int Immunopharmacol 2004;4:1329-1341.
33. la Sala A, Gadina M, Kelsall BL. G (i)-protein-dependent inhibition of IL-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase B/Akt pathway and JNK. J Immunol 2005;175:2994-2999.
34. Hillmen P, Young NS, Schubert J, Brodsky RA, Socié G, Muus P, et al. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2006;355:1233-1243.